You are here

Management of Targeted Therapies: PD1 in lung cancer

By Richard Gralla, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

32 - Richard Gralla ANG

In his presentation, Richard Gralla reviews new approaches to treating non-small-cell lung cancer and puts the PD-1 pathway into context. Nowadays, there are at least three distinct treatment strategies: chemotherapy, genetic abnormalities such as mutations or rearrangements and immune checkpoint inhibition. Outcomes differ, for example, according to smoking status and gender. Newer pathways have the potential to identify individual patients likely to respond to treatment. However, chemotherapy remains the largest contributor to survival benefit for the whole population.

Richard Gralla, A. Einstein School of Medicine, NY, USA

Search this site

Featured videos

Free access to ebooks on cachexia and CINV

 

Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

and
Cancer cachexia: mechanisms and progress in treatment

 

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share